Initial and cumulative treatment exposure in patients with advanced-stage grade 1 to 2 FL
| . | Era 1 (1960-1975) N = 147 N (%) . | Era 2 (1976-1986) N = 330 N (%) . | Era 3 (1987-1996) N = 380 N (%) . | Era 4 (1997-2003) N = 213 N (%) . |
|---|---|---|---|---|
| Initial therapy | ||||
| Radiotherapy only* | 37 (25) | 46 (14) | 11 (3) | 6 (3) |
| Single-agent alkylator* | 35 (24) | 60 (18) | 68 (18) | 13 (6) |
| CVP-like* | 68 (46) | 150 (45) | 125 (33) | 110 (52) |
| CHOP-like* | 1 (1) | 17 (5) | 49 (13) | 11 (5) |
| Fludarabine-based* | 0 | 0 | 38 (10) | 4 (2) |
| Rituximab-chemotherapy* | 0 | 0 | 7 (2) | 19 (9) |
| Rituximab* | 0 | 0 | 7 (2) | 19 (9) |
| SCT** | 0 | 3 (1) | 19 (5) | 2 (1) |
| Unknown or no treatment*** | 6 (4) | 53 (16) | 57 (15) | 30 (14) |
| Cumulative treatment exposure in advanced-stage patients by era | ||||
| Radiotherapy | 59 (40) | 86 (26) | 46 (12) | 17 (8) |
| Single-agent alkylator | 60 (41) | 110 (35) | 91 (24) | 17 (8) |
| CVP-like | 97 (66) | 205 (62) | 163 (43) | 113 (53) |
| CHOP-like | 37 (25) | 106 (32) | 106 (28) | 32 (15) |
| Fludarabine-based | 2 (1) | 10 (3) | 87 (23) | 17 (8) |
| Rituximab | 1 (1) | 36 (11) | 103 (27) | 98 (46) |
| Vaccine trial | 1 (1) | 10 (3) | 99 (26) | 60 (28) |
| SCT | 0 | 10 (3) | 65 (17) | 19 (9) |
| Salvage regimen without SCT | 0 | 3 (1) | 11 (3) | 6 (3) |
| . | Era 1 (1960-1975) N = 147 N (%) . | Era 2 (1976-1986) N = 330 N (%) . | Era 3 (1987-1996) N = 380 N (%) . | Era 4 (1997-2003) N = 213 N (%) . |
|---|---|---|---|---|
| Initial therapy | ||||
| Radiotherapy only* | 37 (25) | 46 (14) | 11 (3) | 6 (3) |
| Single-agent alkylator* | 35 (24) | 60 (18) | 68 (18) | 13 (6) |
| CVP-like* | 68 (46) | 150 (45) | 125 (33) | 110 (52) |
| CHOP-like* | 1 (1) | 17 (5) | 49 (13) | 11 (5) |
| Fludarabine-based* | 0 | 0 | 38 (10) | 4 (2) |
| Rituximab-chemotherapy* | 0 | 0 | 7 (2) | 19 (9) |
| Rituximab* | 0 | 0 | 7 (2) | 19 (9) |
| SCT** | 0 | 3 (1) | 19 (5) | 2 (1) |
| Unknown or no treatment*** | 6 (4) | 53 (16) | 57 (15) | 30 (14) |
| Cumulative treatment exposure in advanced-stage patients by era | ||||
| Radiotherapy | 59 (40) | 86 (26) | 46 (12) | 17 (8) |
| Single-agent alkylator | 60 (41) | 110 (35) | 91 (24) | 17 (8) |
| CVP-like | 97 (66) | 205 (62) | 163 (43) | 113 (53) |
| CHOP-like | 37 (25) | 106 (32) | 106 (28) | 32 (15) |
| Fludarabine-based | 2 (1) | 10 (3) | 87 (23) | 17 (8) |
| Rituximab | 1 (1) | 36 (11) | 103 (27) | 98 (46) |
| Vaccine trial | 1 (1) | 10 (3) | 99 (26) | 60 (28) |
| SCT | 0 | 10 (3) | 65 (17) | 19 (9) |
| Salvage regimen without SCT | 0 | 3 (1) | 11 (3) | 6 (3) |